MDMA-assisted psychotherapy

Zinger Keypoints: Long-term (over 1 year) follow-up reflects lasting improvements in symptom severity. Data confirms prior Phase 2 studies on MDMA-assisted therapy’s sustained effect on PTSD treatment. New Drug Application (NDA) to be submitted in Q3 2023 would be the last...

Psychedelics biotech Awakn Life Sciences (OTCQB: AWKNF) has initiated a feasibility study of formulating and delivering MDMA through Catalent’s proprietary oral, fast-dissolving tablet Zydis technology. The new drug delivery platform is a freeze-dried, oral solid dosage form that rapidly...

In recent months, the psychedelics space has been ground for increasing collaborations. In some cases it was to advance scientific studies. In others, to offer psychedelic medicine, therapy training and clinical retreats.   This time, a partnership has been set between Sunstone...

In a welcomed throwback to the days before psychedelic use and research was considered a forbidden topic, the conference “Horizons: Perspectives On Psychedelics” in New York City is an incredible testimony to where the field of psychedelic therapy, and the industry as a whole, is...